EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
What Changes at Scale, and How Do You Know?
A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...
Advisory Board
KNOWLEDGE BANK
-
Articles
Navigating Gene Therapy Regulations: Compliance Strategies for Successful Implementation
Gene therapy holds immense promise for treating a wide range of genetic disorders and diseases However its implementation requires strict adherence to regulatory guidelines to ensure safety efficacy and ethical considerations
Quantum Dot: The Future of Personalized Medicine
Cancer is amongst the most significant health hazards around the globe Individualized chemotherapy offers promise for the forthcoming cancer therapy in clinical practice with each patient receiving tailored medication based on essential biological aspects of a specific tumor One of the most pressing issues is the development of innovative ways for personalized
Personalized Medicine and Longevity: Advancing the Frontier
The world is experiencing a profound demographic shift with population aging impacting healthcare economies and human rights The United Nations projects that by the number of people aged and over will double to billion comprising one in six people worldwide United Nations OHCHR By older adults will likely outnumber children necessitating a rethink of health aging and longevity Hartmann Young
Innovative Pricing Models in the EU: Making Medicines Affordable for All
Pricing policies are important determinants in delivering sufficiently cheap medicines in all the member nations of the EU High costs of meeting the required medical care together with arising independent differentiated technological improvements have rendered exhausted pricing structures as uncompetitive tools for fairness New mechanisms of pricing have been introduced
Advanced 3D Cell Models: Moving from Promise to Practice in Drug Discovery
Over the past decade organoids spheroids and other advanced D cell models have transformed how researchers approach disease modelling and drug development Their ability to better reflect human biology than traditional D cultures has generated significant enthusiasm across pharmaceutical research yet widespread adoption remains a work in progress
AI-Native R&D: Transforming Drug Discovery Through Intelligent Automation
For four decades pharmaceutical research productivity has moved stubbornly in the wrong direction A new medicine still takes ten to fifteen years to reach patients at a capitalised cost approaching US billion
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Quantum Dot: The Future of Personalized Medicine
Chandan Adhikari
Certainly, we are all alike, but we are all unique. And the notion that medication would be used in a way that overlooks those disparities is as absurd as walking to a sneaker store to pick up any old...
-
2
Personalized Medicine and Longevity: Advancing the Frontier
Dr. KaT Zarychta
Personalized medicine and longevity research are converging to advance healthcare frontiers. Innovations like genomic profiling, AI-driven diagnostics, and targeted interventions enable precision appr...
-
3
Innovative Pricing Models in the EU: Making Medicines Affordable for All
Debi Jones
In this article, we discuss new approaches to drug pricing in the EU: value based pricing, risk sharing, subscription and differential pricing. These strategies are to achieve cost reduction for medic...
-
4
Advanced 3D Cell Models: Moving from Promise to Practice in Drug Discovery
Nicola Bevan
Advanced 3D cell models have been hailed as the future of drug discovery for more than a decade, yet their routine use in pharmaceutical research remains surprisingly limited. As organoids, spheroids...
-
5
AI-Native R&D: Transforming Drug Discovery Through Intelligent Automation
Lakshmi
Artificial intelligence has moved beyond pilot projects into the architecture of pharmaceutical research itself. This article examines the shift from AI-enabled to AI-native R&D, in which closed-l...
press releases Read more...
Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery
As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company
Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
Sanofi announced today that the European Commission has approved VaxRabeo rabies virus inactivated strain Wistar for preexposure prophylaxis PrEP and postexposure prophylaxis PEP against rabies for all age groups
Datapharm appoints healthcare leaders to help shape the future of trusted medicines information
Datapharm the company behind emc the UKs trusted source of regulatorapproved medicines information today announced the formation of its Strategic Advisory Board bringing together senior figures from across pharma medical affairs and patient advocacy
London Biotechnology Show 2026 Concludes Two-Day Event, Bringing Global Life Sciences Community Together
The third edition of the London Biotechnology Show has concluded at ExCeL London following two days of discussions technology showcases and industry engagement that brought together stakeholders from across the global biotechnology and life sciences ecosystem
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWS Read more...
DISCO Pharmaceuticals Partners with AbbVie to Develop Next-Generation Bispecific Therapies for Solid Tumours
DISCO Pharmaceuticals has entered into a strategic collaboration and optiontolicense agreement with AbbVie to discover and develop nextgeneration ANDgated bispecific therapies for solid tumours with significant unmet medical needs
CAI Enters Agreement with PQE Group to Expand Global Life Sciences Services
CAI a professional services firm specialising in operational readiness and excellence for life sciences and other critical industries has entered into a definitive agreement with PQE Group a global consulting firm focused on quality compliance
Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer
Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS
Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications
Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU
FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer
Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer
European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer
Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...









